The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Update on the Pathogenesis and Therapy of Atopic Dermatitis
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent eczematous lesions and intense itch. Although it most often starts in infancy and affects children, it is also highly prevalent in adults. In this article, the main aspects of AD have been updated, with a focus on the pathogenetic and therapeutic aspects. The pathogenesis of AD is complex, and it is evident that a strong genetic predisposition, epidermal dysfunction, skin microbiome abnormalities, immune dysregulation, and the neuroimmune system are critical in AD development. Mutations in the genes associated with disrupted epidermal barrier, exaggerated pathological inflammation and inadequate antimicrobial peptides can promote enhanced Th2 inflammation and mediate pruritus. Current understanding of etiology highlights gut microbial diversity, NK cell deficiency, and different immunological phenotype with age and race. For topical anti-inflammatory treatment for mild-to-severe AD, phosphodiesterase 4 inhibitors (PDE-4), JAK inhibitors, and microbiome transplantation with Roseomonas mucosa provided more management selections. The treatment of moderate-to-severe AD has been limited to merely symptomatic and relatively nonspecific immunosuppressive approaches. In-depth understanding of the pathogenesis of AD has led to the development of innovative and targeted therapies, such as biologic agents targeting interleukin (IL)-4, IL-13 and JAK/STAT inhibitors. Other potential therapeutic agents…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Distinct cytokine axes, including Th2-associated cytokines (IL-4, IL-13), the IL-17, IL-23 axis, and cytotoxic IFN-γ-mediated pathways, form the core of major inflammatory skin diseases discussed in this review.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“In parallel, neuroimmune mechanisms have emerged as important modulators of cytokine signaling, linking neuronal pathways to immune activation and contributing to disease symptoms such as pruritus [2,6].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“The IL-4/IL-13 axis signals through JAK-dependent pathways with downstream activation of STAT6, which is central to type 2 inflammation”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“while IL-17 and IL-23 drive keratinocyte activation and chronic inflammation in psoriasis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“These morphological and molecular features directly underpin the development of targeted drugs such as dupilumab, tralokinumab, and lebrikizumab.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“A total of 65% of patients in the dupilumab combined with TCS group achieved an EASI 75 compared with 22% treated with TCS only [95].”
ResultLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Filaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217 · cited 1×
“The FLG variants R501X and 2282del4 were found in approximately 10% of Northern Europeans [15], while FLG variants of P478S and 3321delA were found mainly in Asian AD populations, and rarely in European populations [16].”
BackgroundWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181 · cited 3×
“Oral food challenge of AD patients may induce early reactions such as urticaria, gastrointestinal or respiratory symptoms usually occurring within 2 h after allergen administration (IgE-mediated), or eczematous late-phase responses after 18–48 h (none IgE-mediated) [61].”
BackgroundInfluentialTight junction defects in patients with atopic dermatitis
De Benedetto, A., Rafaels, N. M., McGirt, L. Y., Ivanov, A. I., Georas, S. N., Cheadle, C., Berger, A. E., Zhang, K., Vidyasagar, S., Yoshida, T., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.018 · Cited by 747 · cited 1×
“Genetic barrier defects decrease the expression of epidermal differentiation-related molecules, such as loricrin and involucrin and tight junction proteins claudin-1 and claudin-23, which are inversely correlated with Th2 biomarkers [20].”
BackgroundThe burden of atopic dermatitis: summary of a report for the National Eczema Association.
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.012 · Cited by 720 · cited 1×
“Due to its increasing incidence, AD is now a huge economic burden for families and society [2].”
BackgroundWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657 · cited 1×
“The Asian AD phenotype presented with a blended phenotype between that of European American AD and those with psoriasis, of which the skin biopsies exhibited higher Th17 activation and a strong Th2 component [42].”
Background
Cited by
Recent advances in understanding the role of IL-4 signaling
Keegan, A. D., Leonard, W. J., & Zhu, J. (2021) · Faculty Reviews · doi:10.12703/r/10-71 · Cited by 154
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
Crocetti, L., Floresta, G., Cilibrizzi, A., & Giovannoni, M. P. (2022) · Molecules · doi:10.3390/molecules27154964 · Cited by 129
Huang, F., Lu, X., Kuai, L., Ru, Y., Jiang, J., Song, J., Chen, S., Mao, L., Li, Y., Li, B., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11059 · Cited by 114
Tsiogka, A., Kyriazopoulou, M., Kontochristopoulos, G., Nicolaidou, E., Stratigos, A., Rigopoulos, D., & Gregoriou, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154431 · Cited by 103
“Current knowledge suggests that robust activation of the T-helper (Th)-2 [interleukin (IL)-4, IL-5, IL-13, IL-31] and Th22 (IL-22) immune responses in both skin and serum play a pivotal role in the immunopathogenesis of AD especially at the acute stage, followed by a variable degree of Th1[interferon-γ (IFN-γ), tumor…”
BackgroundLimosilactobacillus reuteri in immunomodulation: molecular mechanisms and potential applications
Luo, Z., Chen, A., Xie, A., Liu, X., Jiang, S., & Yu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228754 · Cited by 93
Metadata
- Authors
- Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Guo, Yifeng
- Yao, Zhirong
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2021-08-02
- Volume
- 61
- Issue
- 3
- Pages
- 324-338
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- OpenAlex
- W3192687721
- Semantic Scholar
- 2455c8867c90afc6e1d277b48077606f29743af5
- Cited by
- 277
- References
- 141
- Citations by year
- 2026: 43 · 2025: 77 · 2024: 84 · 2023: 46 · 2022: 25 · 2021: 2
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Reviews in Allergy & Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, pathogenesis, skin barrier dysfunction, skin microbiome, immune dysregulation, type 2 inflammation, pruritus, NK cell deficiency, gut microbiota, Roseomonas mucosa, microbiota transplantation, phosphodiesterase-4 inhibitors, JAK inhibitors, IL-23/Th17 pathway, topical corticosteroids, antipruritic therapy, probiotics
- MeSH terms
- Dermatitis, Atopic, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on the Pathogenesis and Therapy of Atopic Dermatitis. https://app.cochat.ai/papers/10.1007/s12016-021-08880-3
- The paper
- Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021). Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-021-08880-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.